John R Murren

Summary

Affiliation: Yale University
Country: USA

Publications

  1. ncbi Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule
    J R Murren
    Yale Cancer Center, New Haven, Connecticut, USA
    Oncology (Williston Park) 15:25-30. 2001
  2. ncbi Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer
    John R Murren
    Yale University School of Medicine, New Haven, Connecticut 06520 8032, USA
    Cancer Biol Ther 4:1311-5. 2005
  3. ncbi Phase I study of perillyl alcohol in patients with refractory malignancies
    John R Murren
    Departments of Medicine, Pharmacology, Obstetrics and Gynecology, Cancer Center, Yale University School of Medicine, 333 Cedar St, NSB 287, New Haven, Connecticut 06520, USA
    Cancer Biol Ther 1:130-5. 2002
  4. ncbi Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer
    Eric Bleickardt
    Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Biol Ther 1:646-51. 2002
  5. ncbi Camptothecin and taxane regimens for small-cell lung cancer
    Myron S Kwong
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06520-8032, USA
    Oncology (Williston Park) 16:33-8. 2002
  6. ncbi A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer
    Erole M Hobdy
    Yale University School of Medicine, New Haven, Connecticut 06520-8032, USA
    Cancer Biol Ther 3:89-93. 2004
  7. ncbi Angiogenesis in non-small cell lung cancer. A new target for therapy
    Tracy E Kim
    Department of Internal Medicine, Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Am J Respir Med 1:325-38. 2002
  8. ncbi Progress in the therapy of small cell lung cancer
    Miklos Simon
    Section of Medical Oncology, Yale University School of Medicine, P.O. Box 208032, 333 Cedar Str #287 NSB, New Haven, CT 06520-8032, USA
    Crit Rev Oncol Hematol 49:119-33. 2004
  9. ncbi Therapy for stage IIIB and stage IV non-small cell lung cancer
    Tracy E Kim
    Department of Internal Medicine, Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Chest Med 23:209-24. 2002
  10. ncbi Erlotinib OSI/Roche/Genentech
    Tracy E Kim
    Yale University School of Medicine, 333 Cedar St, New Haven, CT 06520, USA
    Curr Opin Investig Drugs 3:1385-95. 2002

Research Grants

  1. Radioisotope Therapy Targeting the Somatostatin Receptor
    Gina Chung; Fiscal Year: 2003
  2. Improved Use of Camptothecins for Small Cell Lung Cancer
    John Murren; Fiscal Year: 2004

Collaborators

Detail Information

Publications11

  1. ncbi Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule
    J R Murren
    Yale Cancer Center, New Haven, Connecticut, USA
    Oncology (Williston Park) 15:25-30. 2001
    ..The most common nonhematologic toxicities remain asthenia, neuropathy, and diarrhea. Future studies will explore and better define the role of these drug combinations in the treatment of lung cancer...
  2. ncbi Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer
    John R Murren
    Yale University School of Medicine, New Haven, Connecticut 06520 8032, USA
    Cancer Biol Ther 4:1311-5. 2005
    ..We conducted a phase II study to evaluate the efficacy and safety of the combination of irinotecan and paclitaxel in patients with advanced stage non-small cell lung cancer (NSCLC)...
  3. ncbi Phase I study of perillyl alcohol in patients with refractory malignancies
    John R Murren
    Departments of Medicine, Pharmacology, Obstetrics and Gynecology, Cancer Center, Yale University School of Medicine, 333 Cedar St, NSB 287, New Haven, Connecticut 06520, USA
    Cancer Biol Ther 1:130-5. 2002
    ..Further development of perillyl alcohol on this schedule would be facilitated by reformulation of the capsule...
  4. ncbi Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer
    Eric Bleickardt
    Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Biol Ther 1:646-51. 2002
    ..Phase II trials of this regimen are ongoing or planned in lung, head and neck, stomach, esophageal, and pancreatic cancers...
  5. ncbi Camptothecin and taxane regimens for small-cell lung cancer
    Myron S Kwong
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06520-8032, USA
    Oncology (Williston Park) 16:33-8. 2002
    ..The combination of taxanes and irinotecan holds promise as an active regimen that may be tolerated better than cisplatin and irinotecan...
  6. ncbi A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer
    Erole M Hobdy
    Yale University School of Medicine, New Haven, Connecticut 06520-8032, USA
    Cancer Biol Ther 3:89-93. 2004
    ..This incidence is unacceptably high and indicates better selection criteria are needed in order to exclude patients at excessive risk of morbidity...
  7. ncbi Angiogenesis in non-small cell lung cancer. A new target for therapy
    Tracy E Kim
    Department of Internal Medicine, Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Am J Respir Med 1:325-38. 2002
    ....
  8. ncbi Progress in the therapy of small cell lung cancer
    Miklos Simon
    Section of Medical Oncology, Yale University School of Medicine, P.O. Box 208032, 333 Cedar Str #287 NSB, New Haven, CT 06520-8032, USA
    Crit Rev Oncol Hematol 49:119-33. 2004
    ..Novel molecular targeted therapies are among the strategies currently being investigated in SCLC...
  9. ncbi Therapy for stage IIIB and stage IV non-small cell lung cancer
    Tracy E Kim
    Department of Internal Medicine, Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Chest Med 23:209-24. 2002
    ..Many of these novel target modulators likely will require combination with conventional chemotherapy for optimal results...
  10. ncbi Erlotinib OSI/Roche/Genentech
    Tracy E Kim
    Yale University School of Medicine, 333 Cedar St, New Haven, CT 06520, USA
    Curr Opin Investig Drugs 3:1385-95. 2002
    ..In October 2001, phase III monotherapy trials in NSCLC and phase III combination trials in pancreatic cancer were also initiated [426704]. In Japan, the compound was in phase I studies in January 2002 [439189]...
  11. ncbi Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel
    Vanita Noronha
    Section of Medical Oncology, Yale Comprehensive Cancer Center, 333 Cedar Street, PO Box 208032, New Haven, CT 06520-8032, USA
    Lancet Oncol 7:270-1. 2006

Research Grants2

  1. Radioisotope Therapy Targeting the Somatostatin Receptor
    Gina Chung; Fiscal Year: 2003
    ..These translational studies will serve as the basis for expanding a novel therapeutic modality for neuroendocrine cancers. ..
  2. Improved Use of Camptothecins for Small Cell Lung Cancer
    John Murren; Fiscal Year: 2004
    ..The data generated by these studies will provide additional insight into clinically relevant mechanisms of resistance to camptothecin that occur in SCLC. ..